Ua hoʻolaha ʻo Adiso Therapeutics, Inc. i kēia lā ua hoʻopau ʻo ia i ka hoʻopaʻa inoa ʻana o kāna hui mua o nā maʻi ma kahi haʻawina hoʻokolohua Phase 1b e loiloi ana i ka ADS051 (BT051), he mea hoʻoponopono waha, hoʻopaʻa ʻia, modulator liʻiliʻi o ka neutrophil trafficking a me ka hoʻōla ʻana, ma ke ʻano he lapaʻau kūpono. no nā poʻe maʻi me ka maʻi ulcerative colitis (UC). Ua hōʻike ʻia nā ʻikepili makapō he palekana a ʻae ʻia ka dosing ma kēia cohort, e kākoʻo ana i ka hoʻomaka ʻana o ke kākau inoa ʻana o ka cohort kiʻekiʻe ʻelua.
ʻO kēia Phase 1b kahi haʻawina randomized, double-blind, placebo-controlled, multiple ascending dose study i nā maʻi me UC moderately-to-severely active (NCT05084261). ʻO nā pahuhopu mua o kēia haʻawina ʻo ka palekana a me ka hoʻomanawanui me ka pahuhopu lua o ka pharmacokinetics, a me nā pahuhopu ʻimi no ka hōʻemi ʻana i nā biomarkers pili i ka neutrophil. Ke hahai nei kēia haʻawina Phase 1b i kahi haʻawina piʻi ʻana hoʻokahi o ka Phase 1 i nā mea manawaleʻa olakino i hōʻike ʻia ʻo ADS051 i hoʻopaʻa ʻia me ka loaʻa ʻole o nā mea ʻawaʻawa a i ʻole nā hanana pōʻino koʻikoʻi.
"ʻO ka huli ʻana i nā neutrophils kahi hoʻolālā hou no ka mālama ʻana i ka pathophysiology kumu o ka ulcerative colitis. ʻO kēia haʻawina Phase 1b ka hana hou aʻe i ka ʻimi ʻana pehea e hiki ai i ka ADS051 ke pale palekana i nā ala koʻikoʻi i ʻike ʻia ke kumu o ka neʻe ʻana a me ka hoʻāla ʻana o nā neutrophils i loko o ke kolonā kahi e hoʻomau ʻia ai ke kaʻina inflammatory acute ma UC. Ma kēia noiʻi e ʻimi mākou i nā biomarkers o ka hana pharmacological a me nā hōʻailona mua o ka hana lapaʻau e hiki ke unuhi i ka hoʻemi ʻana i ka ʻāʻī colonic a hoʻoikaika i ka ho'ōla mucosal i nā maʻi me ka UC haʻahaʻa a paʻakikī, "wahi a Scott Megaffin, Luna Nui, Adiso. "He mea koʻikoʻi ka hoʻomau ʻana i ka hoʻomohala ʻana i ka lāʻau lapaʻau o ADS051 i ka pono nui ʻole o ka poʻe maʻi me ka UC i loaʻa ka liʻiliʻi o nā lāʻau lapaʻau i hoʻopaʻa ʻia i ka neutrophil trafficking."